CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2070.0
(-1.66%)
KRW 2070.0
(-1.66%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 43.7 Billion KRW | 6.85% |
| 2022 | 40.9 Billion KRW | 22.27% |
| 2021 | 33.45 Billion KRW | 7.18% |
| 2020 | 31.21 Billion KRW | 24.83% |
| 2019 | 25 Billion KRW | 1471.44% |
| 2018 | 1.59 Billion KRW | 13.01% |
| 2017 | 1.4 Billion KRW | 23.48% |
| 2016 | 1.14 Billion KRW | -32.5% |
| 2015 | 1.68 Billion KRW | 8.84% |
| 2014 | 1.55 Billion KRW | 29.1% |
| 2013 | 1.2 Billion KRW | 17.06% |
| 2012 | 1.02 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.59 Billion KRW | 1.87% |
| 2024 Q1 | 10.39 Billion KRW | 12.68% |
| 2023 Q2 | 12.91 Billion KRW | 19.57% |
| 2023 FY | 43.7 Billion KRW | 6.85% |
| 2023 Q4 | 9.22 Billion KRW | -14.31% |
| 2023 Q1 | 10.79 Billion KRW | 1.05% |
| 2023 Q3 | 10.76 Billion KRW | -16.61% |
| 2022 Q3 | 884.63 Million KRW | 1.04% |
| 2022 FY | 40.9 Billion USD | 22.27% |
| 2022 Q4 | 10.68 Billion KRW | 1108.05% |
| 2022 Q2 | 875.56 Million KRW | 16.8% |
| 2022 Q1 | 749.64 Million KRW | 4.63% |
| 2021 Q1 | 683.46 Million KRW | 13.59% |
| 2021 FY | 33.45 Billion USD | 7.18% |
| 2021 Q2 | 750.12 Million KRW | 9.75% |
| 2021 Q3 | 754 Million KRW | 0.52% |
| 2021 Q4 | 716.47 Million KRW | -4.98% |
| 2020 Q3 | 580.64 Million KRW | 35.3% |
| 2020 Q1 | 459.62 Million KRW | -6.0% |
| 2020 Q2 | 429.14 Million KRW | -6.63% |
| 2020 FY | 31.21 Billion USD | 24.83% |
| 2020 Q4 | 601.68 Million KRW | 3.62% |
| 2019 Q2 | 492.97 Million KRW | 9.73% |
| 2019 Q4 | 488.96 Million KRW | 3.56% |
| 2019 Q1 | 449.23 Million KRW | 12.98% |
| 2019 Q3 | 472.14 Million KRW | -4.22% |
| 2019 FY | 25 Billion USD | 1471.44% |
| 2018 FY | 1.59 Billion USD | 13.01% |
| 2018 Q4 | 397.61 Million KRW | 0.35% |
| 2018 Q3 | 396.23 Million KRW | -6.73% |
| 2018 Q2 | 424.81 Million KRW | 14.08% |
| 2018 Q1 | 372.36 Million KRW | 9.48% |
| 2017 Q1 | 340.22 Million KRW | 10.39% |
| 2017 Q2 | 384.08 Million KRW | 12.89% |
| 2017 Q3 | 343.44 Million KRW | -10.58% |
| 2017 FY | 1.4 Billion USD | 23.48% |
| 2017 Q4 | 340.1 Million KRW | -0.97% |
| 2016 FY | 1.14 Billion USD | -32.5% |
| 2016 Q4 | 308.2 Million KRW | -1.45% |
| 2016 Q3 | 312.73 Million KRW | 1.8% |
| 2016 Q2 | 307.2 Million KRW | 44.89% |
| 2016 Q1 | 212.02 Million KRW | -36.08% |
| 2015 Q2 | 465.48 Million KRW | 12.79% |
| 2015 Q1 | 412.68 Million KRW | 3.8% |
| 2015 FY | 1.68 Billion USD | 8.84% |
| 2015 Q4 | 331.71 Million KRW | -30.8% |
| 2015 Q3 | 479.37 Million KRW | 2.98% |
| 2014 Q4 | 397.57 Million KRW | -6.0% |
| 2014 Q3 | 422.96 Million KRW | 5.18% |
| 2014 Q2 | 402.14 Million KRW | 22.11% |
| 2014 Q1 | 329.31 Million KRW | 5.68% |
| 2014 FY | 1.55 Billion USD | 29.1% |
| 2013 Q1 | 268.07 Million KRW | 6.32% |
| 2013 FY | 1.2 Billion USD | 17.06% |
| 2013 Q3 | 310.56 Million KRW | -0.43% |
| 2013 Q2 | 311.9 Million KRW | 16.35% |
| 2013 Q4 | 311.62 Million KRW | 0.34% |
| 2012 Q4 | 252.13 Million KRW | 0.0% |
| 2012 FY | 1.02 Billion USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 82.98 Billion KRW | 47.337% |
| Celltrion Pharm, Inc. | 116.95 Billion KRW | 62.634% |
| Huons Global Co., Ltd. | 417.8 Billion KRW | 89.54% |
| DongKook Pharmaceutical Co., Ltd. | 405.04 Billion KRW | 89.21% |
| Enzychem Lifesciences Corporation | 3.29 Billion KRW | -1226.941% |
| Humedix Co., Ltd. | 68.04 Billion KRW | 35.774% |
| Boditech Med Inc. | 76.7 Billion KRW | 43.025% |
| EuBiologics Co., Ltd. | 32.65 Billion KRW | -33.815% |
| FutureChem Co.,Ltd | 758.27 Million KRW | -5663.466% |
| Huons Co., Ltd. | 285.93 Billion KRW | 84.716% |
| BNC Korea Co., Ltd. | 31.97 Billion KRW | -36.665% |
| AptaBio Therapeutics Inc. | 78.49 Million KRW | -55573.045% |